This study investigates advanced pancreatic adenocarcinoma. The purpose is to explore the effects of an investigational medication combined with chemotherapy and immunotherapy.
The study evaluates the safety and effectiveness of combining different treatments to understand their impact on the condition.
- Who can participate: Participants must be 18 years or older with confirmed pancreatic adenocarcinoma and meet specific health criteria, including adequate organ function.
- Study details: Participants will receive an investigational medication along with chemotherapy and immunotherapy. Some may receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.